The global market for prescription respiratory drugs encompasses a wide variety of products that treat both common everyday respiratory illnesses as well as serious chronic conditions such as COPD. Technological developments and improved delivery methods have given many health professionals a wider range of products to treat patients with respiratory diseases and have expanded the market for respiratory pharmaceuticals.
This comprehensive study of the market for prescription pharmaceutical products to treat respiratory illness examines six distinct drug segments:
- Anti-inflammatories, Inhaled Corticosteroids
- Mast Stabilizers, Leukotriene Modifiers, and Other Biologics
- Antihistamines, Decongestants, and Antitussives
- Lung Fluid Replacement and Mucokinetic Agents
- Other Respiratory Drugs
Each section provides particulars on the currently available pharmaceutical products in that class, the development pipeline (including developer and development stage), and detailed market data on the segment, including:
- Historical revenue performance 2000-2005
- Revenue projections through 2010
- Geographic revenue breakdown (U.S. vs non-U.S.)
- Epidemiology of the relevant conditions
- Revenues and market shares of the leading suppliers.
The report also reviews the major drivers and constraints in the respiratory drug market as well as the issues and trends in healthcare more generally that will impact this segment in the coming years and profiles the major competitors in the area, including AstraZeneca, Bayer Corporation, Boehringer Ingelheim, Eli Lilly, Genentech, GlaxoSmithKline, MedImmune, Merck & Co., Pfizer, Sanofi-Aventis, and Schering-Plough.
The information and analysis presented in this report are based on extensive interviews with senior management of top companies in the respiratory drug market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with 42 industry executives and product managers to validate and obtain expert opinion on current and future trends in the respiratory market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.